Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SAMIR T ABDELSHAHEED

Allopathic & Osteopathic Physicians Family Medicine

NPI
1598720245
CMS profile
71562
Location
CHESAPEAKE, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,062.31

125 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,062.31 125

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SAMIR T ABDELSHAHEED

NPI 1598720245 · CMS profile ID 71562

Allopathic & Osteopathic Physicians / Family Medicine

CHESAPEAKE, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598720245?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SAMIR T ABDELSHAHEED, NPI 1598720245, CMS profile ID 71562. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598720245?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SAMIR T ABDELSHAHEED, NPI 1598720245, CMS profile ID 71562. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598720245?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SAMIR T ABDELSHAHEED, NPI 1598720245, CMS profile ID 71562, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1598720245?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

125 matching records · $2,062.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 125 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 125.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $4.1807/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996077635 CMS
Novartis Pharmaceuticals Corporation $18.1207/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991780199 CMS
PFIZER INC. $14.9107/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049347313 CMS
AstraZeneca Pharmaceuticals LP $20.6107/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012087989 CMS
GlaxoSmithKline, LLC. $16.8807/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002080195 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.9407/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057247403 CMS
AstraZeneca Pharmaceuticals LP $25.1207/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014546035 CMS
Amgen Inc. $15.8507/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020671867 CMS
PFIZER INC. $20.5207/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049275786 CMS
AbbVie Inc. $21.4207/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996077633 CMS
AstraZeneca Pharmaceuticals LP $23.1007/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014754537 CMS
Lilly USA, LLC $14.6807/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032159957 CMS
Novo Nordisk Inc $15.3807/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385191 CMS
AbbVie Inc. $12.4507/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996077631 CMS
Janssen Pharmaceuticals, Inc $14.2607/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988129613 CMS
AbbVie Inc. $10.1406/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996077629 CMS
AbbVie Inc. $8.1306/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996077627 CMS
Novartis Pharmaceuticals Corporation $17.7106/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991780187 CMS
AstraZeneca Pharmaceuticals LP $13.0406/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011383005 CMS
PFIZER INC. $20.1706/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049127001 CMS
AbbVie Inc. $17.9506/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996077625 CMS
AstraZeneca Pharmaceuticals LP $12.9806/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015380449 CMS
PFIZER INC. $20.0506/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050582901 CMS
PFIZER INC. $2.1806/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050410095 CMS
Exact Sciences Corporation $17.3306/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026669369 CMS
PFIZER INC. $20.8306/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049139463 CMS
AbbVie Inc. $17.7805/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996077623 CMS
Merck Sharp & Dohme LLC $13.1905/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048643077 CMS
Boston Scientific Corporation $14.1905/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022433955 CMS
Janssen Pharmaceuticals, Inc $15.6105/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988129697 CMS
AbbVie Inc. $12.7005/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996077621 CMS
AstraZeneca Pharmaceuticals LP $22.0005/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011292185 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.8805/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057194419 CMS
AstraZeneca Pharmaceuticals LP $24.4505/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014893163 CMS
Janssen Pharmaceuticals, Inc $0.9305/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988129679 CMS
Janssen Pharmaceuticals, Inc $9.0505/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988129689 CMS
Novo Nordisk Inc $21.4705/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385239 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.8305/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057329091 CMS
Bayer Healthcare Pharmaceuticals Inc. $16.0905/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000088091 CMS
PFIZER INC. $16.4105/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050578929 CMS
Lilly USA, LLC $16.2304/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032159952 CMS
Novo Nordisk Inc $11.7104/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000385173 CMS
Exact Sciences Corporation $18.0404/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026669357 CMS
AstraZeneca Pharmaceuticals LP $23.6504/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011787251 CMS
Janssen Pharmaceuticals, Inc $17.7004/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988129661 CMS
PFIZER INC. $18.2504/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050705355 CMS
AstraZeneca Pharmaceuticals LP $17.8503/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011671739 CMS
E.R. Squibb & Sons, L.L.C. $23.7703/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015829331 CMS
AstraZeneca Pharmaceuticals LP $24.8503/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016068713 CMS
Bayer Healthcare Pharmaceuticals Inc. $20.8403/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000146477 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,309.78 106
PY2020 $1,599.00 106
PY2021 $2,248.14 141
PY2022 $2,311.07 138
PY2023 $2,062.31 125
PY2024 $2,027.32 114
PY2025 $1,473.59 72

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $363,316.35 101
PY2024 Recipient $715.00 1
PY2024 Principal investigator $261,096.70 55
PY2019 Principal investigator $4,485.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

101 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,200.00 12/17/2025 Non-covered Recipient Entity
CENTRICITY FMHC, LLC
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185548713
Principal investigator 1 Janssen Research & Development, LLC $334.00 12/03/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207884
Principal investigator 1 Janssen Research & Development, LLC $362.00 12/03/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207915
Principal investigator 1 Janssen Research & Development, LLC $910.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207637
Principal investigator 1 Janssen Research & Development, LLC $600.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207662
Principal investigator 1 Janssen Research & Development, LLC $640.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207668
Principal investigator 1 Janssen Research & Development, LLC $128.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207688
Principal investigator 1 Janssen Research & Development, LLC $600.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207749
Principal investigator 1 Janssen Research & Development, LLC $128.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207763
Principal investigator 1 Janssen Research & Development, LLC $78.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207819
Principal investigator 1 Janssen Research & Development, LLC $128.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207839
Principal investigator 1 Janssen Research & Development, LLC $128.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207864
Principal investigator 1 Janssen Research & Development, LLC $384.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207936
Principal investigator 1 Janssen Research & Development, LLC $910.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207955
Principal investigator 1 Janssen Research & Development, LLC $284.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207996
Principal investigator 1 Janssen Research & Development, LLC $384.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175208014
Principal investigator 1 Janssen Research & Development, LLC $600.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175208021
Principal investigator 1 Janssen Research & Development, LLC $128.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175208047
Principal investigator 1 Janssen Research & Development, LLC $78.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175208071
Principal investigator 1 Janssen Research & Development, LLC $462.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175208132
Principal investigator 1 Janssen Research & Development, LLC $128.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175208138
Principal investigator 1 Janssen Research & Development, LLC $718.00 12/01/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175208145
Principal investigator 1 ModernaTX, Inc. $250.00 12/01/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974911
Principal investigator 1 ModernaTX, Inc. $500.00 12/01/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974943
Principal investigator 1 ModernaTX, Inc. $200.00 12/01/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $125.00 11/19/2025 Non-covered Recipient Entity
Centricity Research - Suffolk Primary Care - Centricity - PPDS
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508833
Principal investigator 1 ModernaTX, Inc. $30.00 11/19/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974973
Principal investigator 1 ModernaTX, Inc. $390.00 11/19/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974995
Principal investigator 1 ModernaTX, Inc. $400.00 11/03/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974923
Principal investigator 1 ModernaTX, Inc. $390.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974967
Principal investigator 1 ModernaTX, Inc. $30.00 10/29/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974997
Principal investigator 1 ModernaTX, Inc. $1,414.40 10/24/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974931
Principal investigator 1 ModernaTX, Inc. $440.15 10/17/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974909
Principal investigator 1 AstraZeneca Pharmaceuticals LP $64,801.35 10/08/2025 Non-covered Recipient Entity
CENTRICITY FMHC, LLC
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185548711
Principal investigator 1 ModernaTX, Inc. $4,243.20 09/19/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974951
Principal investigator 1 ModernaTX, Inc. $780.00 09/12/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974913
Principal investigator 1 ModernaTX, Inc. $60.00 09/12/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974919
Principal investigator 1 ModernaTX, Inc. $30.00 08/27/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975005
Principal investigator 1 Amgen Inc. $25,698.54 08/26/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246640183
Principal investigator 1 ModernaTX, Inc. $2,156.70 08/22/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974915
Principal investigator 1 ModernaTX, Inc. $50.00 08/15/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974981
Principal investigator 1 ModernaTX, Inc. $440.15 08/01/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974935
Principal investigator 1 ModernaTX, Inc. $2,364.70 07/23/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974939
Principal investigator 1 ModernaTX, Inc. $390.00 07/11/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974921
Principal investigator 1 ModernaTX, Inc. $60.00 07/11/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974947
Principal investigator 1 ModernaTX, Inc. $390.00 07/09/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974953
Principal investigator 1 ModernaTX, Inc. $60.00 07/09/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974971
Principal investigator 1 ModernaTX, Inc. $1,000.00 07/07/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974917
Principal investigator 1 ModernaTX, Inc. $30.00 07/02/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974941
Principal investigator 1 ModernaTX, Inc. $320.00 07/02/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974959
Principal investigator 1 ModernaTX, Inc. $400.00 07/02/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974961
Principal investigator 1 ModernaTX, Inc. $440.15 07/02/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974979
Principal investigator 1 ModernaTX, Inc. $6,451.90 06/18/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975003
Principal investigator 1 SANOFI PASTEUR INC. $2,425.00 06/18/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088319
Principal investigator 1 ModernaTX, Inc. $100.00 06/13/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974933
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,849.84 06/12/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190308890
Principal investigator 1 SANOFI PASTEUR INC. $400.00 06/09/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088314
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 06/06/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207630
Principal investigator 1 Janssen Research & Development, LLC $480.00 06/05/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207793
Principal investigator 1 ModernaTX, Inc. $60.00 06/04/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974925
Principal investigator 1 SANOFI PASTEUR INC. $400.00 06/02/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088302
Principal investigator 1 ModernaTX, Inc. $4,863.30 05/28/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974929
Principal investigator 1 ModernaTX, Inc. $30.00 05/28/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974985
Principal investigator 1 Janssen Research & Development, LLC $502.00 05/20/2025 Non-covered Recipient Entity
Centricity Fmhc Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175207681
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 05/08/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088273
Principal investigator 1 ModernaTX, Inc. $30.00 05/01/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975001
Principal investigator 1 Janssen Research & Development, LLC $236.20 04/30/2025 Non-covered Recipient Entity
Suffolk Multispecialty Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175294926
Principal investigator 1 Janssen Research & Development, LLC $6,210.33 04/30/2025 Non-covered Recipient Entity
Suffolk Multispecialty Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175294962
Principal investigator 1 ModernaTX, Inc. $1,446.90 04/18/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974989
Principal investigator 1 Janssen Research & Development, LLC $148.00 04/17/2025 Non-covered Recipient Entity
Suffolk Multispecialty Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175294972
Principal investigator 1 Janssen Research & Development, LLC $16,470.00 04/15/2025 Non-covered Recipient Entity
Suffolk Multispecialty Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175294980
Principal investigator 1 SANOFI PASTEUR INC. $4,870.14 04/15/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088279
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 04/15/2025 Non-covered Recipient Entity
Cr Services Acquisition Us Llc
A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. No dispute reported 06/30/2026 1226088292
Principal investigator 1 Janssen Research & Development, LLC $2,528.00 03/25/2025 Non-covered Recipient Entity
Suffolk Multispecialty Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175294932
Principal investigator 1 ModernaTX, Inc. $240.00 03/21/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974907
Principal investigator 1 ModernaTX, Inc. $3,829.80 03/19/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974987
Principal investigator 1 Janssen Research & Development, LLC $128.00 03/17/2025 Non-covered Recipient Entity
Suffolk Multispecialty Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175294939
Principal investigator 1 ModernaTX, Inc. $400.00 03/14/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974965
Principal investigator 1 ModernaTX, Inc. $30.00 03/12/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974949
Principal investigator 1 ModernaTX, Inc. $90.00 03/12/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974975
Principal investigator 1 ModernaTX, Inc. $30.00 03/12/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974991
Principal investigator 1 Novartis Pharmaceuticals Corporation $58,019.17 03/10/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH SUFFOLK PRIMARY CARE
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190306041
Principal investigator 1 ModernaTX, Inc. $120.00 03/05/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974983
Principal investigator 1 ModernaTX, Inc. $6,854.90 02/26/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974993
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,306.50 02/25/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH SUFFOLK PRIMARY CARE
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190306039
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,486.00 02/25/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190308886
Principal investigator 1 Janssen Research & Development, LLC $900.00 02/19/2025 Non-covered Recipient Entity
Suffolk Multispecialty Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175294949
Principal investigator 1 ModernaTX, Inc. $500.00 02/14/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974927
Principal investigator 1 ModernaTX, Inc. $400.00 02/14/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974945
Principal investigator 1 ModernaTX, Inc. $400.00 02/12/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974955
Principal investigator 1 ModernaTX, Inc. $400.00 02/05/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974937
Principal investigator 1 ModernaTX, Inc. $30.00 02/05/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974969
Principal investigator 1 ModernaTX, Inc. $30.00 02/03/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974977
Principal investigator 1 Eli Lilly and Company $418.61 01/31/2025 Non-covered Recipient Entity
COLUMBUS CLINICAL RESEARCH INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878061
Principal investigator 1 ModernaTX, Inc. $802.00 01/29/2025 Non-covered Recipient Entity
SUFFOLK MULTISPECIALTY RESEARCH LLC
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults No dispute reported 06/30/2026 1252974957
Principal investigator 1 ModernaTX, Inc. $2,861.30 01/24/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252974999
Principal investigator 1 Eli Lilly and Company $26,505.32 01/21/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC DBA CENTRICITY RESEARCH
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187878467
Principal investigator 1 Janssen Research & Development, LLC $148.00 01/21/2025 Non-covered Recipient Entity
Suffolk Multispecialty Research, Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175294956
Principal investigator 1 AstraZeneca Pharmaceuticals LP $30,319.20 01/17/2025 Non-covered Recipient Entity
CR SERVICES ACQUSITION US, LLC
A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension No dispute reported 06/30/2026 1185548715
Principal investigator 1 Amgen Inc. $26,369.60 01/13/2025 Non-covered Recipient Entity
CENTRICITY RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246640185
Principal investigator 1 ModernaTX, Inc. $500.00 01/03/2025 Non-covered Recipient Entity
CENTRICITY FMHC LLC
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252975007